Innova Captab announced in an exchange filing that it has begun commercial production at its advanced manufacturing facility located in Kathua, Jammu.

This facility features four specialized manufacturing blocks: General, Cephalosporin, Penicillin, and Penum, and is equipped to produce a wide variety of products, including oral solid dosages, dry powder injectables, dry syrups, BFS, large volume parenterals, and respiratory respule products.

With this new development, the company now operates a total of five manufacturing facilities at a consolidated level, which include nine separate manufacturing blocks.

“This marks a significant milestone in our growth journey, enhancing both our production capacity and product basket. This will also enhance our ability to meet the evolving needs of our customers. This expansion is a strategic step in line with our long-term vision to strengthen our market position and fuel sustainable growth,” said Vinay Lohariwala, Managing Director in an exchange filing.

The firm also stated that the facility has been set up with an investment exceeding Rs 450 crore, and with the commencement of commercial production, the Company is well-positioned to gain from the Central Government's 'New Central Sector Scheme,’ which offers a 6% per annum Capital Interest Subvention and a GST-linked incentive amounting to 300% of the investment in plant and machinery within a 10-year period.